Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
While engagement of the inhibitory Fcγ-receptor (FcγR) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement for human mAbs has been disputed. By using a mouse model humanized for its FcγRs and CD40, we revealed that FcγRIIB engagement is essential for the activity of human CD40 mAbs, while engagement of the activating FcγRIIA inhibits this activity. By engineering Fc variants with selective enhanced binding to FcγRIIB, but not to FcγRIIA, significantly improved antitumor immunity was observed. These findings highlight the necessity of optimizing the Fc domain for this class of therapeutic antibodies by using appropriate preclinical models that accurately reflect the unique affinities and cellular expression of human FcγR..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cancer cell - 29(2016), 6, Seite 820-831 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dahan, Rony [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1016/j.ccell.2016.05.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1978589638 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1978589638 | ||
| 003 | DE-627 | ||
| 005 | 20230517112036.0 | ||
| 007 | tu | ||
| 008 | 160719s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2016.05.001 |2 doi | |
| 028 | 5 | 2 | |a PQ20160719 |
| 035 | |a (DE-627)OLC1978589638 | ||
| 035 | |a (DE-599)GBVOLC1978589638 | ||
| 035 | |a (PRQ)c1039-5d43261cef5cb58196c1047b62c7cd216c97df860d7c82b0d6dd1c2f3c3cdc840 | ||
| 035 | |a (KEY)0486579020160000029000600820therapeuticactivityofagonistichumananticd40monoclo | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 610 |q DNB |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Dahan, Rony |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a While engagement of the inhibitory Fcγ-receptor (FcγR) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement for human mAbs has been disputed. By using a mouse model humanized for its FcγRs and CD40, we revealed that FcγRIIB engagement is essential for the activity of human CD40 mAbs, while engagement of the activating FcγRIIA inhibits this activity. By engineering Fc variants with selective enhanced binding to FcγRIIB, but not to FcγRIIA, significantly improved antitumor immunity was observed. These findings highlight the necessity of optimizing the Fc domain for this class of therapeutic antibodies by using appropriate preclinical models that accurately reflect the unique affinities and cellular expression of human FcγR. | ||
| 540 | |a Nutzungsrecht: Copyright © 2016 Elsevier Inc. All rights reserved. | ||
| 700 | 1 | |a Barnhart, Bryan C |4 oth | |
| 700 | 1 | |a Li, Fubin |4 oth | |
| 700 | 1 | |a Yamniuk, Aaron P |4 oth | |
| 700 | 1 | |a Korman, Alan J |4 oth | |
| 700 | 1 | |a Ravetch, Jeffrey V |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d Cambridge, Mass. : Cell Press, 2002 |g 29(2016), 6, Seite 820-831 |w (DE-627)346650461 |w (DE-600)2078448-X |w (DE-576)100517854 |x 1535-6108 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2016 |g number:6 |g pages:820-831 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.ccell.2016.05.001 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27265505 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.81 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 29 |j 2016 |e 6 |h 820-831 | ||